Please assess the completion status of the following clinical trial:

Trial Title: Adherence to HIV Therapy in Heroin Addicts: Oral vs XR-NTX

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* must be HIV+ men/women starting their first episode of ART or starting a new ART treatment episode and was prescribed medications that suppressed the virus to \<400 copies during their last treatment~* understand that they will be prescribed ART medications that they have never received and to which their virus is likely to be susceptible~* viral loads of 1,000 copies or more~* meet the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) criteria for opioid dependence in early remission~* have a negative opiate urine toxicology and alcohol breath test~* show no evidence of physiologic dependence on physical exam and following a naltrexone challenge~* have a stable address in the St. Petersburg or Leningrad Region of Russia area~* have a valid telephone number where subject can be reached~* have a negative pregnancy test and use adequate contraception~* have the ability to give informed consent as judged by ability to read the consent and correctly answer 9 of 10 questions about the study on a quiz that will be administered after discussing the study and reading the consent~Exclusion Criteria:~* not be currently psychotic as determined by a psychiatric examination (i.e.; schizophrenia, paranoid disorder, mania)~* not have current suicidal or homicidal ideation requiring immediate attention as determined at baseline assessment~* not have an uncontrolled seizure disorder~* not have cognitive impairment with an inability to read and understand the consent~* not have significant laboratory abnormality such as \>2 grade anemia~* not have hepatic transaminase levels \>5 times the upper limit of normal~* not have serum creatinine \>1.5 times the upper limit of normal~* not have pending legal charges with impending incarceration~* not be concurrently participating in another treatment study~* not currently taking naltrexone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Oral Naltrexone + ART (Type: ACTIVE_COMPARATOR): Naltrexone (oral). 50 mg maintenance daily for 48 weeks, plus group drug counseling manual driven, N= 100
- Naltrexone Implant + ART (Type: ACTIVE_COMPARATOR): Naltrexone Implant + ART. Monthly maintenance for 48 Weeks plus, group drug counseling manual driven, N=100

Based on this trial design, predict the completion outcome and termination type (if applicable).